Generics Should Get REMS Exemption For Sample Collection, GPhA Says
Executive Summary
FDA should create a system to allow generic firms that want to develop ANDAs for products in closed distribution systems to obtain samples from the brand sponsors, the Generic Pharmaceutical Association says
You may also be interested in...
Brand/Generic Battles Over REMS Raise Constitutional Questions For FDA
ANDA sponsors may increasingly face a new roadblock to FDA approval: a Risk Evaluation and Mitigation Strategy (REMS) that restricts access to samples of the brand name product.
Brand/Generic Battles Over REMS Raise Constitutional Questions For FDA
ANDA sponsors may increasingly face a new roadblock to FDA approval: a Risk Evaluation and Mitigation Strategy (REMS) that restricts access to samples of the brand name product.
Playing It Too Safe?: FTC Investigating Use Of REMS To Block Generics
The Federal Trade Commission is looking into whether companies are using their Risk Evaluation and Mitigation Strategies to thwart generic competition.